ALKS vs PACS

ALKS presents a stark dichotomy between financial stability and operational growth. While the deterministic health is strong, evidenced by a Piotroski F-Score of 8/9 and a negligible Debt/Equity ratio of 0.04, the company is suffering from severe earnings contraction (-67% YoY) and negative revenue growth. The stock trades at a significant premium to both its Graham Number ($18.8) and Intrinsic Value ($10.01), suggesting the current price is driven by analyst optimism rather than current fundamentals. Despite a 'strong_buy' analyst consensus, insider selling and a deteriorating forward P/E indicate significant valuation risk.

PACS presents a high-growth profile tempered by significant financial leverage and mediocre fundamental health, as evidenced by a Piotroski F-Score of 4/9. While the stock trades near its growth-based intrinsic value ($35.99) and shows an attractive PEG ratio of 1.02, it is priced at a massive premium to its Graham Number ($12.88). Explosive earnings growth is offset by a poor track record of meeting analyst estimates and a high Debt/Equity ratio of 3.78. The divergence between 'Strong Buy' analyst ratings and bearish insider/technical signals suggests a period of volatility ahead.